Antiprotozoal

Last updated

Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.

Contents

A paraphyletic group, protozoans have little in common with each other. For example, Entamoeba histolytica , a unikont eukaryotic organism, is more closely related to Homo sapiens (humans), which also belongs to the unikont phylogenetic group, than it is to Naegleria fowleri , a "protozoan" bikont. As a result, agents effective against one pathogen may not be effective against another.[ citation needed ]

Antiprotozoal agents can be grouped by mechanism [1] or by organism. [2] Recent papers have also proposed the use of viruses to treat infections caused by protozoa. [3] [4]

Overuse or misuse of antiprotozoals can lead to the development of antiprotozoal resistance. [5]

Medical uses

Antiprotozoals are used to treat protozoal infections, which include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis, and toxoplasmosis. [6] Currently, many of the treatments for these infections are limited by their toxicity. [7]

Outdated terminology

Protists were once considered protozoans, but of late the categorization of unicellar organisms has undergone rapid development, however in literature, including scientific, there tends to persist the usage of the term antiprotozoal when they really mean anti-protist. Protists are a supercategory of eukaryota which includes protozoa.

Mechanism

The mechanisms of antiprotozoal drugs differ significantly drug to drug. For example, it appears that eflornithine, a drug used to treat trypanosomiasis, inhibits ornithine decarboxylase, while the aminoglycoside antibiotic/antiprotozoals used to treat leishmaniasis are thought to inhibit protein synthesis. [8]

Examples

Related Research Articles

<span class="mw-page-title-main">African trypanosomiasis</span> Parasitic disease also known as sleeping sickness

African trypanosomiasis, also known as African sleeping sickness or simply sleeping sickness, is an insect-borne parasitic infection of humans and other animals. It is caused by the species Trypanosoma brucei. Humans are infected by two types, Trypanosoma brucei gambiense (TbG) and Trypanosoma brucei rhodesiense (TbR). TbG causes over 92% of reported cases. Both are usually transmitted by the bite of an infected tsetse fly and are most common in rural areas.

<span class="mw-page-title-main">Leishmaniasis</span> Disease caused by parasites of the Leishmania type

Leishmaniasis is a wide array of clinical manifestations caused by parasites of the Trypanosomatida genus Leishmania. It is generally spread through the bite of phlebotomine sandflies, Phlebotomus and Lutzomyia, and occurs most frequently in the tropics and sub-tropics of Africa, Asia, the Americas, and southern Europe. The disease can present in three main ways: cutaneous, mucocutaneous, or visceral. The cutaneous form presents with skin ulcers, while the mucocutaneous form presents with ulcers of the skin, mouth, and nose. The visceral form starts with skin ulcers and later presents with fever, low red blood cell count, and enlarged spleen and liver.

<span class="mw-page-title-main">Parasitic disease</span> Medical condition

A parasitic disease, also known as parasitosis, is an infectious disease caused by parasites. Parasites are organisms which derive sustenance from its host while causing it harm. The study of parasites and parasitic diseases is known as parasitology. Medical parasitology is concerned with three major groups of parasites: parasitic protozoa, helminths, and parasitic arthropods. Parasitic diseases are thus considered those diseases that are caused by pathogens belonging taxonomically to either the animal kingdom, or the protozoan kingdom.

<span class="mw-page-title-main">Parasitology</span> Study of parasites, their hosts, and the relationship between them

Parasitology is the study of parasites, their hosts, and the relationship between them. As a biological discipline, the scope of parasitology is not determined by the organism or environment in question but by their way of life. This means it forms a synthesis of other disciplines, and draws on techniques from fields such as cell biology, bioinformatics, biochemistry, molecular biology, immunology, genetics, evolution and ecology.

<i>Trichomonas vaginalis</i> Species of parasite that causes sexually transmitted infections

Trichomonas vaginalis is an anaerobic, flagellated protozoan parasite and the causative agent of a sexually transmitted disease called trichomoniasis. It is the most common pathogenic protozoan that infects humans in industrialized countries. Infection rates in men and women are similar but women are usually symptomatic, while infections in men are usually asymptomatic. Transmission usually occurs via direct, skin-to-skin contact with an infected individual, most often through vaginal intercourse. The WHO has estimated that 160 million cases of infection are acquired annually worldwide. The estimates for North America alone are between 5 and 8 million new infections each year, with an estimated rate of asymptomatic cases as high as 50%. Usually treatment consists of metronidazole and tinidazole.

<span class="mw-page-title-main">Trypanosomiasis</span> Medical condition

Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic protozoan trypanosomes of the genus Trypanosoma. In humans this includes African trypanosomiasis and Chagas disease. A number of other diseases occur in other animals.

<span class="mw-page-title-main">Suramin</span> Medical drug

Suramin is a medication used to treat African sleeping sickness and river blindness. It is the treatment of choice for sleeping sickness without central nervous system involvement. It is given by injection into a vein.

<span class="mw-page-title-main">Melarsoprol</span> Medication used to treat sleeping sickness

Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness. It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection into a vein.

Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.

<span class="mw-page-title-main">Equine protozoal myeloencephalitis</span> Central nervous system disease of horses

Equine protozoal myeloencephalitis (EPM), is a disease caused by the apicomplexan parasite Sarcocystis neurona that affects the central nervous system of horses.

Antiparasitics are a class of medications which are indicated for the treatment of parasitic diseases, such as those caused by helminths, amoeba, ectoparasites, parasitic fungi, and protozoa, among others. Antiparasitics target the parasitic agents of the infections by destroying them or inhibiting their growth; they are usually effective against a limited number of parasites within a particular class. Antiparasitics are one of the antimicrobial drugs which include antibiotics that target bacteria, and antifungals that target fungi. They may be administered orally, intravenously or topically. Overuse or misuse of antiparasitics can lead to the development of antimicrobial resistance.

<span class="mw-page-title-main">Boromycin</span> Chemical compound

Boromycin is a bacteriocidal polyether-macrolide antibiotic. It was initially isolated from the Streptomyces antibioticus, and is notable for being the first natural product found to contain the element boron. It is effective against most Gram-positive bacteria, but is ineffective against Gram-negative bacteria. Boromycin kills bacteria by negatively affecting the cytoplasmic membrane, resulting in the loss of potassium ions from the cell. Boromycin has not been approved as a drug for medical use.

<span class="mw-page-title-main">Nitazoxanide</span> Broad-spectrum antiparasitic and antiviral medication

Nitazoxanide, sold under the brand name Alinia among others, is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections. It is indicated for the treatment of infection by Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals and has been repurposed for the treatment of influenza. Nitazoxanide has also been shown to have in vitro antiparasitic activity and clinical treatment efficacy for infections caused by other protozoa and helminths; evidence as of 2014 suggested that it possesses efficacy in treating a number of viral infections as well.

Crithidia fasciculata is a species of parasitic excavates. C. fasciculata, like other species of Crithidia have a single host life cycle with insect host, in the case of C. fasciculata this is the mosquito. C. fasciculata have low host species specificity and can infect many species of mosquito.

<span class="mw-page-title-main">Blastocystosis</span> Medical condition

Blastocystosis refers to a medical condition caused by infection with Blastocystis. Blastocystis is a protozoal, single-celled parasite that inhabits the gastrointestinal tracts of humans and other animals. Many different types of Blastocystis exist, and they can infect humans, farm animals, birds, rodents, amphibians, reptiles, fish, and even cockroaches. Blastocystosis has been found to be a possible risk factor for development of irritable bowel syndrome.

<span class="mw-page-title-main">Protozoan infection</span> Parasitic disease caused by a protozoan

Protozoan infections are parasitic diseases caused by organisms formerly classified in the kingdom Protozoa. They are usually contracted by either an insect vector or by contact with an infected substance or surface and include organisms that are now classified in the supergroups Excavata, Amoebozoa, SAR, and Archaeplastida.

<span class="mw-page-title-main">Protozoa</span> Single-celled eukaryotic organisms that feed on organic matter

Protozoa are a polyphyletic group of single-celled eukaryotes, either free-living or parasitic, that feed on organic matter such as other microorganisms or organic debris. Historically, protozoans were regarded as "one-celled animals".

A trypanocidal agent is an antiprotozoal agent that acts upon trypanosome parasites.

Fexinidazole is a medication used to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Also a potential new treatment for Chagas disease, a neglected tropical disease that affects millions of people worldwide. It is taken by mouth.

The initial version of a classification system of life by British zoologist Thomas Cavalier-Smith appeared in 1978. This initial system continued to be modified in subsequent versions that were published until he died in 2021. As with classifications of others, such as Carl Linnaeus, Ernst Haeckel, Robert Whittaker, and Carl Woese, Cavalier-Smith's classification attempts to incorporate the latest developments in taxonomy., Cavalier-Smith used his classifications to convey his opinions about the evolutionary relationships among various organisms, principally microbial. His classifications complemented his ideas communicated in scientific publications, talks, and diagrams. Different iterations might have a wider or narrow scope, include different groupings, provide greater or lesser detail, and place groups in different arrangements as his thinking changed. His classifications has been a major influence in the modern taxonomy, particularly of protists.

References

  1. Cynthia R. L. Webster (15 June 2001). Clinical pharmacology. Teton NewMedia. pp. 86–. ISBN   978-1-893441-37-8 . Retrieved 2 May 2010.
  2. Anthony J. Trevor; Bertram G. Katzung; Susan B. Masters (11 December 2007). Katzung & Trevor's pharmacology: examination & board review. McGraw-Hill Professional. pp. 435–. ISBN   978-0-07-148869-3 . Retrieved 2 May 2010.
  3. Keen, E. C. (2013). "Beyond phage therapy: Virotherapy of protozoal diseases". Future Microbiology. 8 (7): 821–823. doi:10.2217/FMB.13.48. PMID   23841627.
  4. Hyman, P.; Atterbury, R.; Barrow, P. (2013). "Fleas and smaller fleas: Virotherapy for parasite infections". Trends in Microbiology. 21 (5): 215–220. doi:10.1016/j.tim.2013.02.006. PMID   23540830.
  5. Ouellette, Marc (November 2001). "Biochemical and molecular mechanisms of drug resistance in parasites". Tropical Medicine and International Health. 6 (11): 874–882. doi:10.1046/j.1365-3156.2001.00777.x. ISSN   1360-2276.
  6. Khaw, M; Panosian, C B (1 July 1995). "Human antiprotozoal therapy: past, present, and future". Clinical Microbiology Reviews. 8 (3): 427–439. doi:10.1128/CMR.8.3.427. ISSN   0893-8512. PMC   174634 . PMID   7553575.
  7. Graebin, C.; Uchoa, F.; Bernardes, L.; Campo, V.; Carvalho, I.; Eifler-Lima, V. (1 October 2009). "Antiprotozoal Agents: An Overview". Anti-Infective Agents in Medicinal Chemistry. 8 (4): 345–366. doi:10.2174/187152109789760199. ISSN   1871-5214.
  8. CREEK, DARREN J.; BARRETT, MICHAEL P. (9 January 2017). "Determination of antiprotozoal drug mechanisms by metabolomics approaches". Parasitology. 141 (1): 83–92. doi:10.1017/S0031182013000814. ISSN   0031-1820. PMC   3884841 . PMID   23734876.